Invention Grant
- Patent Title: Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
-
Application No.: US15604556Application Date: 2017-05-24
-
Publication No.: US10647780B2Publication Date: 2020-05-12
- Inventor: Stefan Ewert , Yasser Khder , Alexander Koch
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner LLP.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/42 ; A61K45/06 ; A61K39/00
Abstract:
The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
Public/Granted literature
- US20180022825A1 REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF Public/Granted day:2018-01-25
Information query
